Colchicine has been tested in cancer as a therapeutic drug in 1945 (Ludford, R. J. (1945). Colchicine in the experimental chemotherapy of cancer.). Since then it has been demonstrated that the anti-tubulin action of colchicine which impedes the prosecution of mitosis in metaphase stage may be useful for the treatment of cancer. Due to its toxicity, colchicine has been replaced as an antitubulin agent by taxanes and other antitubulines in the last 20 years. (Zhou, J., & Giannakakou, P. (2005). Targeting microtubules for cancer chemotherapy. Current Medicinal Chemistry-Anti-Cancer Agents, 5(1), 65-71.)
Since the new antitubuline agents like docetacel and paclitaxel entered oncological practice, there was no place for colchicine further development.
Answering your question, colchicine may be used at the experimental level, against lung cancer, but I do not think it will be really useful in the clinical setting.
Clinically acceptable doses of colchicine were tested on hepatocarcinoma cells with interesting results (Lin, Z. Y., Wu, C. C., Chuang, Y. H., & Chuang, W. L. (2013). Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life sciences, 93(8), 323-328.).